Condition: Immune Thrombocytopenic Purpura · Sponsor: New York Medical College
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.
This description comes directly from the study's public registry record.
Erin Morris, RN · 714-964-5359 · erin_morris@nymc.edu
Lauren Harrison, MSN · 617-285-7844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| New York Medical College | Vahalla, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04323748